Barclays analyst Andrew Mok raised the firm’s price target on CVS Health to $65 from $63 and keeps an Equal Weight rating on the shares after taking a detailed look at 2025 Medicare considerations.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Medicare to recalculate quality ratings of Medicare Advantage plans, WSJ reports
- Unusually active option classes on open June 7th
- Beaten-Down CVS Health Stock (NYSE:CVS) Now Looks Like a Bargain
- CVS Health price target lowered to $86 from $101 at JPMorgan
- CVS Health initiated with a Neutral at Baird